Friday the 13th has turned into a horror story for Australian biotech Immutep, whose share price collapsed after it abandoned a pivotal trial of its lead drug. Immutep's ASX-listed stock fell more ...
We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Kimber Streams Kimber Streams is a writer who has been covering laptops and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results